Degnan Chris
- SEC CIK
- 0001741968
In the past year, 1 open-market sale filing worth $37.1K and no purchases.
Current role at each company
- URGN UroGen Pharma Ltd.Chief Financial Officeras of Feb 3, 2026
- GRTX Galera Therapeutics, Inc.Chief Financial Officeras of Mar 14, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $37.1K
- 1 filing
- Net
- −$37.1K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Degnan Chris as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
URGN UroGen Pharma Ltd.
Chief Financial Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2025 (view filing) | Oct 8 | 1 day | Degnan ChrisChief Financial Officer | SSale | −2.20K | $16.85 | −$37.1K | −49.1%2.28K after |
GRTX Galera Therapeutics, Inc.
Chief Financial Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2023 (view filing) | Mar 13 | 1 day | Degnan ChrisChief Financial Officer | PPurchase | +10.0K | $1.96 | +$19.6K | New position10.0K after |